[Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?].
Intravenous human polyclonal immunoglobulins G (IVIg) were initially used as substitutive therapy for primary and secondary immunodeficiencies then for various autoimmune diseases. More recently they were proposed in organ transplant recipients as they induce a decrease of the anti-HLA antibodies titer in HLA immunized patients. Few retrospective and prospective trials have been performed yet, though they clearly show a beneficial effect of IVIg on kidney graft survival. This paper reviews the different potential mechanisms of action of IVIg their use and potential efficacy in organ transplant recipients.
Service de néphrologie A, INSERM U 489, Hôpital Tenon, Paris.
J P
JP
Haymann
D
D
Glotz
D000888:Antibodies, Anti-Idiotypic; D006084:Graft Rejection / Q000628:therapy; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D014181:Transplantation Immunology
D000888:Antibodies, Anti-Idiotypic; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous
Immunoglobulines polyclonales intraveineuses (IVIg): quel intérêt en transplantation?